KAPA · Kairos Pharma, LTD.
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Shares sold short and not yet covered, reported twice monthly. Days to cover is the reported short position divided by average daily volume.
KAPA Short Interest Forecast
Equibles' model estimates 329,201 shares sold short for the August 31, 2026 settlement, -9.6% versus the latest reported position. This model prediction uses FINRA data through August 21, 2026; FINRA's official release is expected September 10, 2026.
Expected Aug 31 short interest
as of Aug 21Peer-relative percentile rank across all stocks reporting short interest at the latest settlement date (2026-08-14). Weighted mean of the available factors (short interest 30%, days to cover 20%, price vs VWAP 15%, short-volume trend 15%, short-interest change 10%, fails-to-deliver 10%) plus catalyst boosts (price spike, volume surge, earnings within days), capped at +20 and clamped to 100.
Short Interest History
| Settlement Date | Current Position | Previous Position | Change | Days to Cover |
|---|---|---|---|---|
|
2026-09-15
Scheduled
FINRA publishes Sep 24
|
— | — | — | — |
|
2026-08-31
Scheduled
FINRA publishes Sep 10
|
— | — | — | — |
| 2026-08-14 | 364,248 | 517,820 | -153,572 | 1.00 |
| 2026-07-31 | 517,820 | 192,173 | +325,647 | 1.00 |
| 2026-07-15 | 192,173 | 155,940 | +36,233 | 1.00 |
| 2026-06-30 | 155,940 | 154,946 | +994 | 1.11 |
| 2026-06-15 | 154,946 | 157,342 | -2,396 | 1.31 |
| 2026-05-29 | 157,342 | 121,325 | +36,017 | 1.00 |
| 2026-05-15 | 121,325 | 125,693 | -4,368 | 1.00 |
| 2026-04-30 | 125,693 | 146,646 | -20,953 | 1.04 |
| 2026-04-15 | 146,646 | 236,224 | -89,578 | 2.18 |
| 2026-03-31 | 236,224 | 198,425 | +37,799 | 2.25 |
| 2026-03-13 | 198,425 | 1,274,209 | -1,075,784 | 1.00 |
| 2026-02-27 | 1,274,209 | 181,710 | +1,092,499 | 1.00 |
| 2026-02-13 | 181,710 | 144,124 | +37,586 | 2.00 |
| 2026-01-30 | 144,124 | 192,015 | -47,891 | 1.00 |
| 2026-01-15 | 192,015 | 106,098 | +85,917 | 1.00 |
| 2025-12-31 | 106,098 | 111,891 | -5,793 | 1.00 |
| 2025-12-15 | 111,891 | 124,743 | -12,852 | 1.00 |
| 2025-11-28 | 124,743 | 125,497 | -754 | 1.00 |
| 2025-11-14 | 125,497 | 239,099 | -113,602 | 1.00 |
| 2025-10-31 | 239,099 | 274,895 | -35,796 | 1.00 |
| 2025-10-15 | 274,895 | 349,546 | -74,651 | 1.00 |
| 2025-09-30 | 349,546 | 361,699 | -12,153 | 1.00 |
| 2025-09-15 | 361,699 | 504,732 | -143,033 | 1.00 |
Full FINRA short interest reporting calendar